EMBLEM CORP COM NPV (OTCMKTS:EMMBF) has been a declining sleepy little stock averaging 30,000 shares a day. Last week EMMBF shares added 40% to get back to near $2.50 a share and added some big volume, in fact on April 10th the stock traded 650,000 shares this is a long way from creeping along at a 30k clip. This brings in all sorts of new players. A look at the chart below shows the 2017 decline + the recent surge.
The catalyst can be traced back to confirmation from Health Canada that its license under the ACMPR will be amended to permit the production of cannabis oils.
“EMBLEM CORP COM NPV (OTCMKTS:EMMBF) CEO, Gordon Fox stated “This is an incredibly important milestone for us as a company,” “With our ability to extract cannabinoids we can now actively execute the business plan we’ve built for our pharmaceutical division.”
“Cannabinoids have real therapeutic value, as evidenced by the products Cesamet, Marinol and Sativex all having been approved as prescription drugs by Health Canada,” says John H. Stewart, CEO of Emblem Corp’s. pharmaceutical division. In addition, there have been numerous reports published in the scientific literature pertaining to the medical use of cannabinoids – with evidence of efficacy in patients with chronic pain, multiple sclerosis, nausea, neuropathic pain, PTSD and wasting syndrome.
“The active components in cannabis will be extracted, purified and incorporated into advanced formulations, in order to enhance their therapeutic utility,” adds Stewart.
Emblem Corp. has invested over $1 million CAD to date into its extraction and purification platform including a supercritical CO2 extractor, purpose built rooms, and analytical equipment.
Find out when $EMMBF stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
EMMBF has stockpiled a significant amount of both bud and trim for extraction and is pleased to announce that, in addition to those rooms in its current facility that will be licensed for extraction under this amendment, Emblem plans to construct a 2,500 sq. ft. dedicated extraction and formulation development laboratory on its property in Paris, ON. Additionally, Emblem has hired three scientists to work exclusively in this division to pursue the development and manufacture of advanced dosage forms of cannabinoids.
This license amendment will enable Emblem to better serve patients by providing a broad range of cannabis products. Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations to cultivate and sell medical marijuana. Emblem carries out its principal activities producing marijuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act and its regulations.
Emblem Corp. (OTCMKTS:EMMBF) has some new players to the party, and last weeks bounce is a sign that things are positively afoot. Everyone is getting into the cannabis sector and investors are snapping up shares. The industry is dividing into the “touch the plant”, and “not touch the plant” and the valuations of these will be marketed-ly different with the NTTP (Not Touch the Plant) group carrying a larger industry multiple than the TTP (Touch the Plant). Emblem understands this and is carving out a niche which is why the stock reversed last week.
The trick for EMMBF stock to move into the higher NTTP multiple category, if they do this they can retrace much of the 38% loss they have on the books so far in 2017. Readers and investors who understand cannabis stocks also want to know. For continuing coverage on shares of $EMMBF stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!